Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients

References

• International Agency for Research on Cancer. Global cancer observatory. Cancer today. 2020 Available from: http://gco.iarc.fr/. Global Cancer Observatory. http://gco.iarc.fr/. Accessed 1022, 2020.
   Google Scholar
• Lee SS, Shin HS, Kim HJ, et al. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol. 2012;18(1):48–55. doi:10.3350/kjhep.2012.18.1.4822511903
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi:10.1371/journal.pmed.100162424691105
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.01929628281
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.2991329624699
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-928620797
   PubMed Web of Science ®Google Scholar
• Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395(1–2):19–26. doi:10.1016/j.cca.2008.05.01018538135
   PubMed Web of Science ®Google Scholar
• Carr BI, Akkiz H, Üsküdar O, et al. HCC with low- and normal-serum alpha-fetoprotein levels. Clin Pract (Lond). 2018;15(1):453–464. doi:10.4172/clinical-practice.100039329576865
   PubMedGoogle Scholar
• Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. DMM Dis Model Mech. 2011;4(2):165–178. doi:10.1242/dmm.00407721324931
   PubMed Web of Science ®Google Scholar
• Affo S, Yu L-X, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol Mech Dis. 2017;12(1):153–186. doi:10.1146/annurev-pathol-052016-100322
   Web of Science ®Google Scholar
• Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49(6):1954–1961. doi:10.1002/hep.2287019434742
   PubMed Web of Science ®Google Scholar
• Cox TR, Bird D, Baker AM, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013;73(6):1721–1732. doi:10.1158/0008-5472.CAN-12-223323345161
   PubMed Web of Science ®Google Scholar
• Grenard P, Bresson-Hadni S, El Alaoui S, Chevallier M, Vuitton DA, Ricard-Blum S. Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. J Hepatol. 2001;35(3):367–375. doi:10.1016/S0168-8278(01)00135-011592598
   PubMed Web of Science ®Google Scholar
• Wong CCL, Tse APW, Huang YP, et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology. 2014;60(5):1645–1658. doi:10.1002/hep.2732025048396
   PubMed Web of Science ®Google Scholar
• Sun Y, Mi W, Cai J, et al. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res. 2008;7(9):3847–3859. doi:10.1021/pr800153s18646787
   PubMed Web of Science ®Google Scholar
• Yu C, Cao Q, Chen P, et al. Tissue transglutaminase 2 exerts a tumor-promoting role in hepatitis B virus-related hepatocellular carcinoma. Tumor Biol. 2016;37(12):16269–16274. doi:10.1007/s13277-016-5425-z
   Google Scholar
• Gulubova MV. Collagen type III and type IV detection in and around human hepatocellular carcinoma. Gen Diagnostic Pathol. 1997;142(3–4):155–163.
   Google Scholar
• Karsdal MA, Henriksen K, Nielsen MJ, et al. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol - Gastrointest Liver Physiol. 2016;311(6):G1009–G1017. doi:10.1152/ajpgi.00283.201627765759
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Kazankov K, Leeming DJ, et al. Markers of collagen remodeling detect clinically significant fibrosis in chronic hepatitis C patients. PLoS One. 2015;10(9):e0137302. doi:10.1371/journal.pone.013730226406331
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Veidal SS, Karsdal MA, et al. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2015;35(2):429–437. doi:10.1111/liv.1270025308921
   PubMed Web of Science ®Google Scholar
• Leeming DJ, Karsdal MA, Byrjalsen I, et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther. 2013;38(9):1086–1096. doi:10.1111/apt.1248424099470
   PubMed Web of Science ®Google Scholar
• Praktiknjo M, Lehmann J, Nielsen MJ, et al. Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. Hepatol Commun. 2018;2(2):211–222. doi:10.1002/hep4.113529404528
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Thorburn D, Leeming DJ, et al. Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2018;48(2):179–189. doi:10.1111/apt.1480629851098
   PubMed Web of Science ®Google Scholar
• Karsdal MA, Hjuler ST, Luo Y, et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. Am J Physiol - Gastrointest Liver Physiol. 2019;316(1):G25–G31. doi:10.1152/ajpgi.00158.201830160980
   PubMed Web of Science ®Google Scholar
• Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 2019;69(3):1075–1086. doi:10.1002/hep.3016330014517
   PubMed Web of Science ®Google Scholar
• Lipton A, Leitzel K, Ali SM, et al. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int J Cancer. 2018;143(11):3027–3034. doi:10.1002/ijc.3162729923614
   PubMed Web of Science ®Google Scholar
• Jensen C, Madsen DH, Hansen M, et al. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. J Immunother Cancer. 2018;6(1):152. doi:10.1186/s40425-018-0474-z30567561
   PubMed Web of Science ®Google Scholar
• Liu SB, Ikenaga N, Peng ZW, et al. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J. 2016;30(4):1599–1609. doi:10.1096/fj.14-26842526700732
   PubMed Web of Science ®Google Scholar
• Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5(3):303–315.23634241
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837. doi:10.2307/25315953203132
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31(4):302–308. doi:10.1097/00004836-200012000-0000711129271
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• Ju MJ, Qiu SJ, Fan J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol. 2009;131(4):498–510. doi:10.1309/AJCP86PPBNGOHNNL19289585
   PubMed Web of Science ®Google Scholar
• Lau EYT, Lo J, Cheng BYL, et al. Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through c-Met/FRA1/HEY1 signaling. Cell Rep. 2016;15(6):1175–1189. doi:10.1016/j.celrep.2016.04.01927134167
   PubMed Web of Science ®Google Scholar
• Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891–906. doi:10.1016/j.cell.2009.10.02719931152
   PubMed Web of Science ®Google Scholar
• Kehlet SN, Willumsen N, Armbrecht G, et al. Age-related collagen turnover of the interstitial matrix and basement membrane: implications of age- and sex-dependent remodeling of the extracellular matrix. PLoS One. 2018;13(3):e0194458. doi:10.1371/journal.pone.019445829596429
   PubMed Web of Science ®Google Scholar
• Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(SUPPL. 1):S100–S107. doi:10.1016/j.jhep.2004.11.01515777564
   PubMed Web of Science ®Google Scholar
• Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin mutations. Int J Cancer. 2004;112(1):44–50. doi:10.1002/ijc.2027915305374
   PubMed Web of Science ®Google Scholar
• Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. doi:10.1038/s41598-017-12834-128993684
   PubMed Web of Science ®Google Scholar
• Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res. 2019;38(1):115. doi:10.1186/s13046-019-1110-630841909
   PubMed Web of Science ®Google Scholar
• Benson AB, Wainberg ZA, Hecht JR, et al. A phase II randomized, double‐blind, placebo‐controlled study of simtuzumab or placebo in combination with gemcitabine for the first‐line treatment of pancreatic adenocarcinoma. Oncologist. 2017;22(3):241. doi:10.1634/theoncologist.2017-002428246206
   PubMed Web of Science ®Google Scholar
• Daneshpour N, Griffin M, Collighan R, Perrie Y. Targeted delivery of a novel group of site-directed transglutaminase inhibitors to the liver using liposomes: a new approach for the potential treatment of liver fibrosis. J Drug Target. 2011;19(8):624–631. doi:10.3109/1061186X.2010.53173121067461
   PubMed Web of Science ®Google Scholar